


FDA Updates Boxed Warning of Benzodiazepines, Adding Risks for Abuse & Addiction

Safety Risk with Higher Dose Tofacitnib

FDA Update: Priority Review for Non-Opioid Treatment & New Warning for Fluoroquinolones

Second Biosimilar Equivalent to Adalimumab

FDA Update: New Boxed Warnings for Opioids & Benzodiazepines; Plus New Drug Safety Labeling Changes Database

Patients with OA Respond to Low-Dose SoluMatrix Meloxicam; Off-Label Use of Ketoconazole Results in Death
